Whichever way you slice it, this is a disappointing CR. Not only is it at a price well below the year's high but it is also incomplete. Money could have been raised easily at 30 cents before the feud broke out. Instead of seizing the opportunity presented, the company has hoped for more. Very bad capital management. I'm pretty bloody annoyed but am sticking with it. Clinical results so far are very encouraging so let's hope OLE news flow can provide SP momentum. The big thing for me is to get all patients enrolled in the phase 2/3 study by the end of the year.
Ann: Trading Halt, page-110
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.005(2.38%) |
Mkt cap ! $81.16M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.0¢ | 20.5¢ | $87.97K | 426.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10300 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 261000 | 3 |
View Market Depth
| Last trade - 15.59pm 26/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |